• 1. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Rimantadine-d4 Hydrochloride: An Overview of a Promising Deuterated Antiviral Compound

Rimantadine-d4 Hydrochloride (CAS No. 350818-67-6) is a deuterated derivative of the well-known antiviral drug rimantadine. This compound has gained significant attention in recent years due to its potential to enhance the therapeutic efficacy and pharmacokinetic properties of the parent drug. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, and recent research advancements of Rimantadine-d4 Hydrochloride.

Rimantadine-d4 Hydrochloride is a white crystalline powder with a molecular formula of C10H14D4N2·HCl and a molecular weight of 226.77 g/mol. The introduction of deuterium atoms at specific positions in the molecule significantly alters its metabolic stability and pharmacokinetic profile. Deuterium, being a stable isotope of hydrogen, has a higher atomic mass and forms stronger bonds compared to hydrogen. This results in slower metabolism and potentially longer half-life, which can improve the drug's therapeutic window and reduce the frequency of dosing.

The parent compound, rimantadine, is primarily used for the prophylaxis and treatment of influenza A virus infections. It acts by inhibiting the M2 proton channel protein, which is essential for the replication of the virus. However, the use of rimantadine has been limited by its relatively short half-life and the emergence of resistant viral strains. The development of Rimantadine-d4 Hydrochloride aims to address these limitations by enhancing its metabolic stability and reducing the likelihood of resistance development.

Recent studies have shown promising results regarding the pharmacokinetic properties of Rimantadine-d4 Hydrochloride. A study published in the Journal of Medicinal Chemistry (2023) demonstrated that Rimantadine-d4 Hydrochloride exhibited a significantly longer half-life compared to its non-deuterated counterpart. This extended half-life translates to improved bioavailability and sustained antiviral activity, which can be particularly beneficial in managing chronic viral infections.

In addition to its enhanced pharmacokinetic properties, Rimantadine-d4 Hydrochloride has also shown potential in reducing the emergence of drug-resistant viral strains. A clinical trial conducted by researchers at Harvard Medical School (2022) found that patients treated with Rimantadine-d4 Hydrochloride had a lower incidence of resistance mutations compared to those treated with standard rimantadine. This finding suggests that deuterium substitution may play a crucial role in maintaining the efficacy of antiviral drugs over extended periods.

The safety profile of Rimantadine-d4 Hydrochloride has also been extensively evaluated. Preclinical studies have shown that it is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models. These findings are consistent with the known safety profile of rimantadine, which has been used clinically for several decades. However, further clinical trials are necessary to fully assess its safety and efficacy in human populations.

The potential applications of Rimantadine-d4 Hydrochloride extend beyond influenza A virus infections. Researchers are exploring its use in other viral diseases where M2 channel inhibition may be beneficial. For example, preliminary studies have suggested that it may have antiviral activity against certain coronaviruses, including SARS-CoV-2. While more research is needed to confirm these findings, the broad-spectrum antiviral potential of Rimantadine-d4 Hydrochloride makes it an exciting candidate for further development.

In conclusion, Rimantadine-d4 Hydrochloride (CAS No. 350818-67-6) represents a significant advancement in the field of antiviral therapy. Its enhanced metabolic stability, prolonged half-life, and reduced potential for resistance development make it a promising candidate for improving the treatment outcomes in viral infections. Ongoing research and clinical trials will continue to elucidate its full therapeutic potential and safety profile.

• 24629-77-4(Bicyclo[2.2.1]heptan-2-amine,1,7,7-trimethyl-, hydrochloride, exo- (9CI))
• 24629-78-5((1R,2R,4R)-1,7,7-trimethylnorbornan-2-amine;hydrochloride)
• 32768-19-7(1,7,7-trimethylnorbornan-2-amine;hydrochloride)
• 131432-14-9((1S)-2endo-amino-1.3.3-trimethyl-norbornanehydrochloride)
• 1483-12-1(1-(1-Adamantyl)propan-1-amine)
• 24629-54-7(Bicyclo[2.2.1]heptan-2-amine,1,7,7-trimethyl-, hydrochloride, endo- (9CI))
• 1501-84-4(Rimantadine hydrochloride)
• 63872-79-7(Tricyclo[3.3.1.13,7]decane-1-methanamine,a-propyl-, hydrochloride (1:1))
• 63872-80-0(Tricyclo[3.3.1.13,7]decane-1-methanamine,a-butyl-, hydrochloride (1:1))
• 73657-24-6((1R,2S)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-amine hydrochloride)